Jazz Pharmaceuticals plc Capital Reinvestment Ratio
Jazz Pharmaceuticals plc capital reinvestment ratio. Jazz Pharmaceuticals plc (J7Z) has a Capital Reinvestment Ratio of 0.05x as of March 2026, meaning it reinvests 0% of its operating cash flow (€408.20 Million) in capital expenditures (€19.70 Million). See J7Z free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Jazz Pharmaceuticals plc (2013–2025)
Capital reinvestment ratio of Jazz Pharmaceuticals plc from 2013 to 2025. This chart tracks Jazz Pharmaceuticals plc's Capital Reinvestment Ratio across 13 annual periods. See J7Z financial flexibility score to measure the company's free cash flow as a share of total liabilities.
Jazz Pharmaceuticals plc Capital Reinvestment Ratio by Year (2013–2025)
Jazz Pharmaceuticals plc capital reinvestment ratio by year from 2013 to 2025. For the full cash flow conversion analysis, see J7Z operating cash flow.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.15x | €1.36 Billion | €209.75 Million | ▲ +349.3% |
| 2024 | 0.03x | €1.40 Billion | €48.07 Million | ▼ -12.5% |
| 2023 | 0.04x | €1.09 Billion | €42.96 Million | ▲ +72.3% |
| 2022 | 0.02x | €1.27 Billion | €29.05 Million | ▼ -35.7% |
| 2021 | 0.04x | €778.51 Million | €27.64 Million | ▲ +112.9% |
| 2020 | 0.02x | €899.65 Million | €15.00 Million | ▼ -67.7% |
| 2019 | 0.05x | €776.40 Million | €40.13 Million | ▲ +102.7% |
| 2018 | 0.03x | €798.90 Million | €20.37 Million | ▼ -39.0% |
| 2017 | 0.04x | €693.09 Million | €28.95 Million | ▼ -86.4% |
| 2016 | 0.31x | €592.39 Million | €181.58 Million | ▲ +353.5% |
| 2015 | 0.07x | €531.94 Million | €35.96 Million | ▼ -24.2% |
| 2014 | 0.09x | €407.61 Million | €36.35 Million | ▲ +157.8% |
| 2013 | 0.03x | €288.43 Million | €9.98 Million | — |